Company news
Antengene Corporation Limited news in 2026
Antengene Corporation Limited's news releases, calls and decks from 2026, newest first.
Next Day Disclosure Return
October 22, 2026
Next Day Disclosure Return
October 21, 2026
Next Day Disclosure Return
October 20, 2026
Next Day Disclosure Return
October 16, 2026
Next Day Disclosure Return
October 15, 2026
Next Day Disclosure Return
October 14, 2026
Next Day Disclosure Return
October 13, 2026
Next Day Disclosure Return
October 12, 2026
Next Day Disclosure Return
October 9, 2026
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
October 8, 2026
Next Day Disclosure Return
October 8, 2026
Next Day Disclosure Return
October 7, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Next Day Disclosure Return
October 6, 2026
Next Day Disclosure Return
October 5, 2026
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
October 2, 2026
Next Day Disclosure Return
October 2, 2026
Next Day Disclosure Return
September 30, 2026
Next Day Disclosure Return
September 29, 2026
2026 Interim report
September 29, 2026
Next Day Disclosure Return
September 28, 2026
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
September 20, 2026
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
September 14, 2026
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
August 24, 2026
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
August 23, 2026
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
August 18, 2026
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
July 20, 2026
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
July 12, 2026
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
June 21, 2026
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
June 9, 2026
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
June 7, 2026
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
June 2, 2026
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
May 27, 2026
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
May 19, 2026
Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
April 17, 2026
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
March 20, 2026
Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
March 17, 2026
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
March 3, 2026
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
March 1, 2026
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
February 24, 2026
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
January 15, 2026